See more : Trans Global Group, Inc. (TGGI) Income Statement Analysis – Financial Results
Complete financial analysis of I-Mab (IMAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of I-Mab, a leading company in the Biotechnology industry within the Healthcare sector.
- China Overseas Land & Investment Limited (CAOVF) Income Statement Analysis – Financial Results
- Radiko Holdings Corp. (GEATF) Income Statement Analysis – Financial Results
- HUTCHMED (China) Limited (HCM) Income Statement Analysis – Financial Results
- Global Arena Holding Inc. (GAHC) Income Statement Analysis – Financial Results
- Applied Genetic Technologies Corporation (AGTC) Income Statement Analysis – Financial Results
I-Mab (IMAB)
About I-Mab
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 27.64M | -221.56M | 88.03M | 1.54B | 30.00M | 53.78M | 11.56M |
| Cost of Revenue | 0.00 | 27.24M | 46.43M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 27.64M | -248.80M | 41.59M | 1.54B | 30.00M | 53.78M | 11.56M |
| Gross Profit Ratio | 100.00% | 112.29% | 47.25% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 114.36M | 904.90M | 1.21B | 984.69M | 840.42M | 426.03M | 267.08M |
| General & Administrative | 63.91M | 815.77M | 899.94M | 402.41M | 654.55M | 66.39M | 25.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 63.91M | 815.77M | 899.94M | 402.41M | 654.55M | 66.39M | 25.44M |
| Other Expenses | 22.93M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 201.20M | 2.28B | 2.40B | 1.08B | 1.51B | 461.42M | 310.58M |
| Cost & Expenses | 201.20M | 2.31B | 2.44B | 1.08B | 1.51B | 461.42M | 310.58M |
| Interest Income | 7.30M | 26.90M | 21.33M | 23.27M | 27.58M | 6.52M | 787.00K |
| Interest Expense | 101.85K | 1.30K | 0.00 | 146.48K | 427.48K | 1.70M | 864.34K |
| Depreciation & Amortization | 23.95M | 25.34M | 13.78M | 12.74M | 9.83M | 6.74M | 1.63M |
| EBITDA | -1.21B | -1.94B | -2.06B | 168.31M | -1.46B | -431.90M | -279.32M |
| EBITDA Ratio | -4,384.57% | 877.46% | -2,337.41% | 10.91% | -4,850.46% | -803.07% | -2,417.11% |
| Operating Income | -1.24B | -1.97B | -2.07B | 155.57M | -1.46B | -438.64M | -280.96M |
| Operating Income Ratio | -4,471.20% | 888.90% | -2,353.06% | 10.08% | -4,883.23% | -815.60% | -2,431.25% |
| Total Other Income/Expenses | -229.68M | -537.15M | -263.39M | 327.58M | 13.02M | 37.53M | -17.29M |
| Income Before Tax | -1.47B | -2.51B | -2.33B | 483.15M | -1.45B | -401.11M | -298.24M |
| Income Before Tax Ratio | -5,302.03% | 1,131.34% | -2,652.28% | 31.32% | -4,839.83% | -745.82% | -2,580.82% |
| Income Tax Expense | -1.26B | 697.00K | 3.15M | 12.23M | 0.00 | 1.72M | 0.00 |
| Net Income | -1.47B | -2.51B | -2.33B | 470.92M | -1.49B | -402.83M | -298.24M |
| Net Income Ratio | -5,302.03% | 1,131.65% | -2,648.70% | 30.53% | -4,950.00% | -749.02% | -2,580.82% |
| EPS | -17.62 | -30.39 | -30.70 | 8.07 | -462.74 | -141.91 | -119.45 |
| EPS Diluted | -17.61 | -30.39 | -30.69 | 6.90 | -462.73 | -141.91 | -119.45 |
| Weighted Avg Shares Out | 83.19M | 82.52M | 75.93M | 68.25M | 3.21M | 2.84M | 2.50M |
| Weighted Avg Shares Out (Dil) | 83.23M | 82.52M | 75.96M | 68.36M | 3.21M | 2.84M | 2.50M |
I-Mab Honored with Top Rankings by Institutional Investor
I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus
I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab
I-Mab Appoints Ruyi He and Rong Shao to Board of Directors
I-Mab Announces Upcoming Participation at June Conferences
Pharmaron, I-Mab And Burning Rock Get Investor Validation From MSCI
I-Mab Showcases Early Data On Uliledlimab/Atezolizumab Combo In Advanced Cancer Settings
I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
I-Mab Added to MSCI China Index
Source: https://incomestatements.info
Category: Stock Reports